Surgery Partners, Inc. (SGRY) P/E Ratio History
Deep ValueTrading at -23.9x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2015–2024
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Surgery Partners, Inc. (SGRY) trades at a price-to-earnings ratio of -23.9x, with a stock price of $14.55 and trailing twelve-month earnings per share of $-0.59.
The current P/E is 112% below its 5-year average of 191.7x. Over the past five years, SGRY's P/E has ranged from a low of 43.0x to a high of 582.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, SGRY trades at a 208% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, SGRY trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SGRY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SGRY Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SGRY P/E vs Peers
Outpatient clinics and surgery centers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $964M | 44.6 | - | -23% | |
| $2B | 14.0 | - | -29% | |
| $589M | 12.7 | - | -15% | |
| $3B | 26.3 | 1.14 | +17% | |
| $2B | 18.1 | 0.90 | +23% | |
| $9B | 6.1 | 0.38 | +37% | |
| $84B | 13.2 | 0.63 | +29% | |
| $15B | 11.1 | 0.34Best | -53% | |
| $426M | 0.8Lowest | - | +197%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SGRY Historical P/E Data (2015–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q2 | Jun 30 2024 | $23.79 | $0.06 | 374.1x | +95% |
| FY2024 Q1 | Mar 31 2024 | $29.83 | $0.33 | 89.4x | -53% |
| FY2023 Q4 | Dec 31 2023 | $31.99 | $0.44 | 72.4x | -62% |
| FY2023 Q3 | Sep 30 2023 | $29.25 | $0.68 | 43.0x | -78% |
| FY2023 Q2 | Jun 30 2023 | $44.99 | $0.11 | 410.5x | +114% |
| FY2023 Q1 | Mar 31 2023 | $34.47 | $0.13 | 266.0x | +39% |
| FY2022 Q4 | Dec 31 2022 | $27.86 | $0.59 | 47.2x | -75% |
| FY2022 Q3 | Sep 30 2022 | $23.40 | $0.36 | 65.2x | -66% |
| FY2022 Q2 | - | $28.92 | $0.36 | 80.6x | -58% |
| FY2017 Q2 | Jun 30 2017 | $22.75 | $0.15 | 150.7x | -21% |
| FY2017 Q1 | Mar 31 2017 | $19.50 | $0.28 | 68.7x | -64% |
| FY2016 Q4 | Dec 31 2016 | $15.85 | $0.19 | 82.9x | -57% |
| FY2016 Q3 | Sep 30 2016 | $20.24 | $0.19 | 105.8x | -45% |
| FY2016 Q2 | - | $17.90 | $0.18 | 102.2x | -47% |
| FY2016 Q1 | - | $13.26 | $0.03 | 526.2x | +175% |
| FY2015 Q4 | - | $20.49 | $0.04 | 582.1x | +204% |
Average P/E for displayed period: 191.7x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SGRY — Frequently Asked Questions
Quick answers to the most common questions about buying SGRY stock.
What is SGRY's P/E ratio?
Surgery Partners, Inc. (SGRY) trailing twelve-month P/E ratio is -23.9x, based on TTM diluted EPS of $-0.59. The 5-year average P/E is 191.7x and the historical range spans 43.0x to 582.1x.
Is SGRY stock overvalued or undervalued?
SGRY trades at -23.9x P/E, below its 5-year average of 191.7x. At the 0th percentile of its historical range (43.0x–582.1x), the stock is priced at a discount to its own history.
Is SGRY stock expensive?
No, SGRY is not expensive on a historical basis. The current P/E of -23.9x is below the 5-year average of 191.7x and sits at the 0th percentile of its valuation range.
What is SGRY's historical P/E range?
Over the past 5 years, SGRY's P/E ratio has ranged from 43.0x to 582.1x, with a median of 102.2x and an average of 191.7x. The current P/E of -23.9x places the stock at the 0th percentile of this range. Full historical data spans 2015–2024.
How does SGRY's P/E compare to the S&P 500?
SGRY trades at -23.9x P/E versus the S&P 500 median of 24.4x. The 198% discount to the market suggests lower growth expectations or perceived higher risk.
How does SGRY's valuation compare to Healthcare peers?
Surgery Partners, Inc. P/E of -23.9x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SGRY's PEG ratio?
SGRY PEG ratio is N/A, based on a P/E of -23.9x and EPS growth of 54.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SGRY's earnings yield?
SGRY earnings yield is N/A, the inverse of its -23.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.